The drug comes at a time when antibiotic resistance worries are high. Here’s why it matters.
Barbara Hesselgrave
Advertisement
Articles by Barbara Hesselgrave
A cure and a bargain?
Advertisement
Latest Updated Articles
Zolgensma: The $2.1 Million DrugAugust 26th 2019
Lefamulin Could Be Vital in the Pneumonia FightOctober 11th 2019
Advertisement
Advertisement
Trending on Drug Topics
1
The Outcome-Based Program That Could Reshape Pharmacists’ Roles
2
Pharmacist-Led Transitions of Care Could Be Crucial in HIV Treatment
3
Wicked Good Cardiometabolic Chat: Ketone Monitoring in Pharmacy Practice
4
The Pharmacy Model Creating New Billing Pathways, Improved Recognition
5